Anti-Infective Agents, 2020, 18, 207-223 MINI-REVIEW ARTICLE

Total Page:16

File Type:pdf, Size:1020Kb

Anti-Infective Agents, 2020, 18, 207-223 MINI-REVIEW ARTICLE Send Orders for Reprints to [email protected] 207 Anti-Infective Agents, 2020, 18, 207-223 MINI-REVIEW ARTICLE ISSN: 2211-3525 eISSN: 2211-3533 Synthetic Methods and Antimicrobial Perspective of Pyrazole Derivatives: An Insight Harish Kumar1, Kushal Kumar Bansal1 and Anju Goyal2,* 1Govt. College of Pharmacy, Rohru, Shimla, Himachal Pradesh, India; 2Chitkara College of Pharmacy, Chitkara University, Punjab, Rajpura 140407, India Abstract: Background: Due to newly emerging microbial infections and the development of re- sistance against cutting-edge therapeutics, innovative and robust medicinal agents are required. Small ring heterocycles, such as pyrazole and its derivatives have been acknowledged to possess myriad biological properties and the presence of pyrazole in clinics like celecoxib, phenylbutazone (anti-inflammatory), CDPPB (antipsychotic), rimonabant (anti-obesity), antipyrine, difenamizole (analgesic), fipronil (broad-spectrum insecticidal), betazole (H2-receptor agonist) and fezolamide (antidepressant) drugs has proven the pharmacological perspective of pyrazole nucleus. Objectives: The current review paper aimed at a recent update made on novel methodologies adopted in the synthesis of pyrazole derivatives with the emphasis on antibacterial (DNA gyrase inhibition) and antifungal activities. A R T I C L E H I S T O R Y Methods: Pyrazole is one of the major tools to be investigated in drug design and discovery. Many studies have been reported by researchers that have claimed the significant biological potential of Received: July 18, 2019 Revised: September 05, 2019 these derivatives. However, numerous studies on pyrazoles compounds shown to exhibit potential Accepted: September 21, 2019 antifungal and antibacterial activities, the focus has also been made on DNA gyrase inhibition. Additionally, some important patents granted to this heterocyclic nucleus related to antimicrobial DOI: potential are also addressed appropriately. 10.2174/2211352517666191022103831 Results: DNA gyrase is a promising biotarget yet to be explored against a number of medicinal agents. The present work provides valuable insight into synthetic methods and antibacterials/antifungal signifi- cance of pyrazoles in general as well as new inhibitors of DNA gyrase in particular. Conclusion: The manuscript constitutes a valuable reference which advocates candidature of pyra- zoles as a potential therapeutic alternative as antibacterial and antifungal agent. Keywords: Pyrazoles, DNA gyrase, antimicrobial activity, patents, anti-inflammatory, antipsychotic. 1. INTRODUCTION in the synthesis of novel medicinal agents with remarkable biological activities. Pyrazole is one such moiety that has Life threatening infectious diseases pose grave concern to widely been investigated and shown promising scope in the human lives for long time. The antibiotics, antimicrobials development of valuable therapeutics [4]. This heterocyclic and anti-infective cover a variety of pharmaceutical com- pharmacophore has five membered, aromatic rings and has pounds that are regimens for treatment against dreaded infec- structural features with two nitrogen atoms at adjacent posi- tions [1]. The rapid development of antimicrobial resistance tions and three carbon atoms. Ludwig Knorr (1883) has been [2], the continuous evolvement of microbes, and mutations known for his pioneering work on pyrazole (1) scaffold. Af- has aggravated the problem thus, discovery of potent and terward, the chemistry of pyrazoles has been extensively affordable antimicrobial agents represents a resilient chal- investigated by numerous researchers and many papers have lenge [3]. The design and robust scientific exploration of been published in this regard [5]. heterocyclic agents with novel modes of actions might lead the solution to this problem in hand. Nitrogen-containing heterocyclic compounds and their derivatives offer ease N N H (1) *Address correspondence to this author at the Chitkara College of Pharma- cy, Chitkara University, Punjab, Rajpura 140407, India; Tel: 9646499252; In pyrazole, nitrogen atom (N1) resembles pyrrole, while E-mail: [email protected] the second nitrogen (N2) is pyridine-like. The unshared elec- 2211-3533/20 $65.00+.00 2020 Bentham Science Publishers Anti-Infective Agents 208 Anti-Infective Agents, 2020, Vol. 18, No. 3 Kumar et al. N N N N H N N R R R R R N HN N N N N N N N N H Fig. (1). Tautomeric forms of un-substituted and substituted pyrazole. trons of nitrogen (N1) are in conjugation with the aromatic methods. One of the best strategies for synthesizing pyrazole system and the unshared electron of the latter is not negotiat- rings are annulations commenced by the condensation of a ed with resonance. This property or the difference in the ni- monosubstituted hydrazine with a carbonyl for example, trogen atoms of pyrazoles offers many reactions with rea- cyclocondensation of α,β-unsaturated carbonyl or 1, 3- di- gents including acids and bases. Another important aspect is carbonyl compounds with hydrazines. Subsequently, a num- the tautomerism in pyrazole since there are three possible ber of researchers elaborated pharmacologically active pyra- tautomers for un-substituted pyrazoles, while five tautomers zole derivatives synthesized through conventional and non- are possible for mono-substituted pyrazoles (Fig. 1) [6-8]. conventional means [23]. In this section of the article, we tried to compile some important methods on the synthesis of Numerous compounds possessing pyrazole moiety have pyrazole derivatives. diverse applications in the pharmaceutical and agrochemical industries. Pyrazole derivatives have emerged as potential Heller et al. proposed one pot synthesis of pyrazole- therapeutics with a broad spectrum of pharmacological and containing compounds by using simple starting material ke- biological activities comprising anti-histaminic [9], antimi- tones and acid chlorides to give 1,3-diketones. The interme- crobial [10], anti-depressant [11], antiviral [12], antitumor diate thus obtained was reacted with hydrazines to give ex- [13] and fungicides [14]. Owing to the diverse biological cellent yields of pyrazoles [24]. Deng et al. suggested a regi- characteristics, various well-understood synthetic methods oselective reaction between nitro-olefins and N- monosubsti- have widely been observed by the medicinal chemists over tuted hydrazones formed nitropyrazolidine in significant the last few decades. The importance of pyrazole derivatives yields [25]. Jiang et al. reported One-pot synthesis of 4- can be revealed by the fact that several drugs, such as, beta- substituted 1,5-diaryl-1Hpyrazole-3-carboxylic acids by ® ® zole (histamine H2 receptor agonist) [15], fipronil (broad- MeONa/LiCl-catalyzed Claisen condensation. The enolated spectrum insecticide) [16], mepirizole® (nonsteroidal anti- lithium salts of diketo ester were made to react with arylhy- inflammatory drug) [17], lonazolac® (nonsteroidal anti- drazine hydrochloride, trifluoroacetic in ethanol followed by inflammatory drug) [18], sildenafil® (treatment of erectile the hydrolysis to furnish pyrazole derivatives in excellent dysfunction and pulmonary arterial hypertension) [19], ri- quantity [26]. Hu et al. introduced an intramolecular oxida- monabant® (anorectic, antiobesity drug) [20], celecoxib® tive carbon-nitrogen coupling using ruthenium (II)catalyst (nonsteroidal anti-inflammatory drug) [21] and fomipizole® and dioxygen gas in the formation of pyrazole derivatives. (treat methanol and ethylene glycol poisoning) [22] have the Ruthenium (II) is a highly proficient catalyst used for the pyrazole pharmacophore and have met tremendous success development of tri- and tetra-substituted pyrazole deriva- in the market. Microbial enzymes are the alternative ap- tives with the wide acceptance of functional groups [27]. proaches that have been developed over the last few decades. Wu et al. designed a series of 3,5-disubstituted pyrazoles Among these, DNA gyrase is an ATP dependent enzyme, from condensations of various tosyl hydrazine, aldehydes which is the ultimate target of novel pyrazole derivatives and and terminal alkynes in toluene and sodium ethoxide at am- has diverse action on microbes. The inhibition of DNA gy- bient temperature [28]. Zhang et al. executed a one-pot syn- rase results in the disruption of DNA synthesis and, subse- thesis of 3,4,5-trisubstituted 1-H-pyrazole derivatives from quently, cell death, thereby showing the killing effect on aromatic aldehyde, vinyl azide and tosyl hydrazine in the microbes. Hence, keeping in view, the significance of pyra- basic medium (Fig. 2) [29]. zole pharmacophore, the present work has been carried out Sha et al. designed a new method for the synthesis of 3,5- to provide a brief overview of recent developments of pyra- diaryl-4-bromopyrazole derivatives. The reaction was pro- zole containing compounds and their antimicrobial activities ceeded via 1,3-dipolar cycloaddition reaction between to- reported in the recent scientific literature. sylhydrazones and gem-dibromoalkenes in the presence of sodium hydroxide to give 3,5-diaryl-4-bromo-3H-pyrazoles. 2. GENERAL METHODS OF PREPARATION OF PY- The product thus formed undergoes the isomerization of 3,5- RAZOLE diaryl-4-bromo-3H-pyrazoles by using the aldehyde hydra- Pyrazole nucleus is an important chemical entity found in zones to obtain 3,5-diaryl-4-bromo-1H-pyrazoles [30]. Hari- numerous pharmacologically potent drugs. The significance gae et al. proposed a procedure for the synthesis
Recommended publications
  • (12) United States Patent (10) Patent No.: US 8,361,492 B2 Tauber Et Al
    USOO8361492B2 (12) United States Patent (10) Patent No.: US 8,361,492 B2 Tauber et al. (45) Date of Patent: *Jan. 29, 2013 (54) DRUG DELIVERY SYSTEMAND METHODS (56) References Cited OF USE U.S. PATENT DOCUMENTS (75) Inventors: Shachar Tauber, Ozark, MO (US); 2003/0017208 A1* 1/2003 Ignatious et al. ............. 424/486 Randall Fuerst, Orangevale, CA (US); 2003/01931 18 A1 10/2003 Bango et al. 2003/0215624 A1 1 1/2003 Layman et al. Keela Davis, Springfield, MO (US); Lyle 2003/0232287 A1 12/2003 Bango Bowman, Pleasanton, CA (US); Gary 2004/0018226 A1 1/2004 Winek et al. Wnek, Cleveland, OH (US); Joseph J. 2005, OO67287 A1 3/2005 Fuerst et al. Bango, Jr., New Haven, CT (US) 2006/0085063 A1* 4/2006 Shastri et al. ................ 623, 141 2006/0171991 A1 8/2006 Bango 2006/0246113 A1 11/2006 Griffith et al. (73) Assignee: Ocugenics, LLC, Orangevale, CA (US) 2008.0002149 A1 1/2008 Fritsch et al. 2009/0217849 A1 9, 2009 Eastin et al. (*) Notice: Subject to any disclaimer, the term of this 2009, 0238858 A1 9, 2009 Kohnet al. patent is extended or adjusted under 35 OTHER PUBLICATIONS U.S.C. 154(b) by 493 days. Office Action issued in related U.S. Appl. No. 12/416,802, dated Sep. This patent is Subject to a terminal dis 17, 2010, 11 pages. claimer. International Search Report and Written Opinion issued in PCT/ US2010/029126, dated Jan. 14, 2011, 11 pages. Kenawy, E.R. et al. “Controlled Release of Ketoprofen from (21) Appl. No.: 12/490,972 electrospun poly(vinyl alcohol) nanofibers' Materials Science & Engineering A 459, pp.
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]
  • Pharmaceutical Appendix to the Harmonized Tariff Schedule
    Harmonized Tariff Schedule of the United States Basic Revision 3 (2021) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States Basic Revision 3 (2021) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2014/0144429 A1 Wensley Et Al
    US 2014O144429A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2014/0144429 A1 Wensley et al. (43) Pub. Date: May 29, 2014 (54) METHODS AND DEVICES FOR COMPOUND (60) Provisional application No. 61/887,045, filed on Oct. DELIVERY 4, 2013, provisional application No. 61/831,992, filed on Jun. 6, 2013, provisional application No. 61/794, (71) Applicant: E-NICOTINE TECHNOLOGY, INC., 601, filed on Mar. 15, 2013, provisional application Draper, UT (US) No. 61/730,738, filed on Nov. 28, 2012. (72) Inventors: Martin Wensley, Los Gatos, CA (US); Publication Classification Michael Hufford, Chapel Hill, NC (US); Jeffrey Williams, Draper, UT (51) Int. Cl. (US); Peter Lloyd, Walnut Creek, CA A6M II/04 (2006.01) (US) (52) U.S. Cl. CPC ................................... A6M II/04 (2013.O1 (73) Assignee: E-NICOTINE TECHNOLOGY, INC., ( ) Draper, UT (US) USPC ..................................................... 128/200.14 (21) Appl. No.: 14/168,338 (57) ABSTRACT 1-1. Provided herein are methods, devices, systems, and computer (22) Filed: Jan. 30, 2014 readable medium for delivering one or more compounds to a O O Subject. Also described herein are methods, devices, systems, Related U.S. Application Data and computer readable medium for transitioning a Smoker to (63) Continuation of application No. PCT/US 13/72426, an electronic nicotine delivery device and for Smoking or filed on Nov. 27, 2013. nicotine cessation. Patent Application Publication May 29, 2014 Sheet 1 of 26 US 2014/O144429 A1 FIG. 2A 204 -1 2O6 Patent Application Publication May 29, 2014 Sheet 2 of 26 US 2014/O144429 A1 Area liquid is vaporized Electrical Connection Agent O s 2.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0078604 A1 Kanios Et Al
    US 20060078604A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0078604 A1 Kanios et al. (43) Pub. Date: Apr. 13, 2006 (54) TRANSDERMAL DRUG DELIVERY DEVICE Related U.S. Application Data INCLUDING AN OCCLUSIVE BACKING (60) Provisional application No. 60/616,861, filed on Oct. 8, 2004. (75) Inventors: David Kanios, Miami, FL (US); Juan A. Mantelle, Miami, FL (US); Viet Publication Classification Nguyen, Miami, FL (US) (51) Int. Cl. Correspondence Address: A 6LX 9/70 (2006.01) DCKSTEIN SHAPRO MORN & OSHINSKY (52) U.S. Cl. .............................................................. 424/449 LLP (57) ABSTRACT 2101 L Street, NW Washington, DC 20037 (US) A transdermal drug delivery system for the topical applica tion of one or more active agents contained in one or more (73) Assignee: Noven Pharmaceuticals, Inc. polymeric and/or adhesive carrier layers, proximate to a non-drug containing polymeric backing layer which can (21) Appl. No.: 11/245,180 control the delivery rate and profile of the transdermal drug delivery system by adjusting the moisture vapor transmis (22) Filed: Oct. 7, 2005 sion rate of the polymeric backing layer. Patent Application Publication Apr. 13, 2006 Sheet 1 of 2 US 2006/0078604 A1 Fis ZZZZZZZZZZZZZZZZZZZ :::::::::::::::::::::::::::::::: Patent Application Publication Apr. 13, 2006 Sheet 2 of 2 US 2006/0078604 A1 3. s s 3. a 3 : 8 g US 2006/0078604 A1 Apr. 13, 2006 TRANSIDERMAL DRUG DELVERY DEVICE 0008. In the “classic' reservoir-type device, the active INCLUDING AN OCCLUSIVE BACKING agent is typically dissolved or dispersed in a carrier to yield a non-finite carrier form, Such as, for example, a fluid or gel.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2008) (Rev
    Harmonized Tariff Schedule of the United States (2008) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2008) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM GADOCOLETICUM 280776-87-6 ABAFUNGIN 129639-79-8 ACIDUM LIDADRONICUM 63132-38-7 ABAMECTIN 65195-55-3 ACIDUM SALCAPROZICUM 183990-46-7 ABANOQUIL 90402-40-7 ACIDUM SALCLOBUZICUM 387825-03-8 ABAPERIDONUM 183849-43-6 ACIFRAN 72420-38-3 ABARELIX 183552-38-7 ACIPIMOX 51037-30-0 ABATACEPTUM 332348-12-6 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABETIMUSUM 167362-48-3 ACIVICIN 42228-92-2 ABIRATERONE 154229-19-3 ACLANTATE 39633-62-0 ABITESARTAN 137882-98-5 ACLARUBICIN 57576-44-0 ABLUKAST 96566-25-5 ACLATONIUM NAPADISILATE 55077-30-0 ABRINEURINUM 178535-93-8 ACODAZOLE 79152-85-5 ABUNIDAZOLE 91017-58-2 ACOLBIFENUM 182167-02-8 ACADESINE 2627-69-2 ACONIAZIDE 13410-86-1 ACAMPROSATE
    [Show full text]
  • Synthesis and Pharmacological Activities of Pyrazole Derivatives: a Review
    Review Synthesis and Pharmacological Activities of Pyrazole Derivatives: A Review Khalid Karrouchi 1,2,3, Smaail Radi 2,*, Youssef Ramli 1, Jamal Taoufik 1, Yahia N. Mabkhot 4,*, Faiz A. Al-aizari 4 and M’hammed Ansar 1 1 Medicinal Chemistry Laboratory, Faculty of Medicine and Pharmacy, Mohammed V University, 10100 Rabat, Morocco; [email protected] (K.K.); [email protected] (Y.R.); [email protected] (J.T.); [email protected] (M.A.) 2 LCAE, Department of Chemistry, Faculty of Sciences, University Mohamed I, 60000 Oujda, Morocco 3 Physicochemical service, Drugs Quality Control Laboratory, Division of Drugs and Pharmacy, Ministry of Health, 10100 Rabat, Morocco 4 Department of Chemistry, Faculty of Science, King Saud University, P.O. Box 2455, Riyadh 11451, Saudi Arabia; [email protected] * Correspondence: [email protected] or [email protected] (S.R.); [email protected] (Y.N.M.); Tel.: +212-536-500-601 (S.R.) Received: 22 November 2017; Accepted: 5 January 2018; Published: 12 January 2018 Abstract: Pyrazole and its derivatives are considered a pharmacologically important active scaffold that possesses almost all types of pharmacological activities. The presence of this nucleus in pharmacological agents of diverse therapeutic categories such as celecoxib, a potent anti-inflammatory, the antipsychotic CDPPB, the anti-obesity drug rimonabant, difenamizole, an analgesic, betazole, a H2-receptor agonist and the antidepressant agent fezolamide have proved the pharmacological potential of the pyrazole moiety. Owing to this diversity in the biological field, this nucleus has attracted the attention of many researchers to study its skeleton chemically and biologically. This review highlights the different synthesis methods and the pharmacological properties of pyrazole derivatives.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2005/0249806A1 Proehl Et Al
    US 2005O249806A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2005/0249806A1 Proehl et al. (43) Pub. Date: Nov. 10, 2005 (54) COMBINATION OF PROTON PUMP Related U.S. Application Data INHIBITOR, BUFFERING AGENT, AND NONSTEROIDAL ANTI-NFLAMMATORY (60) Provisional application No. 60/543,636, filed on Feb. DRUG 10, 2004. (75) Inventors: Gerald T. Proehl, San Diego, CA (US); Publication Classification Kay Olmstead, San Diego, CA (US); Warren Hall, Del Mar, CA (US) (51) Int. Cl." ....................... A61K 9/48; A61K 31/4439; A61K 9/20 Correspondence Address: (52) U.S. Cl. ............................................ 424/464; 514/338 WILSON SONS IN GOODRICH & ROSAT (57) ABSTRACT 650 PAGE MILL ROAD Pharmaceutical compositions comprising a proton pump PALO ALTO, CA 94304-1050 (US) inhibitor, one or more buffering agent and a nonsteroidal ASSignee: Santarus, Inc. anti-inflammatory drug are described. Methods are (73) described for treating gastric acid related disorders and Appl. No.: 11/051,260 treating inflammatory disorders, using pharmaceutical com (21) positions comprising a proton pump inhibitor, a buffering (22) Filed: Feb. 4, 2005 agent, and a nonsteroidal anti-inflammatory drug. US 2005/0249806 A1 Nov. 10, 2005 COMBINATION OF PROTON PUMP INHIBITOR, of the Stomach by raising the Stomach pH. See, e.g., U.S. BUFFERING AGENT, AND NONSTEROIDAL Pat. Nos. 5,840,737; 6,489,346; and 6,645,998. ANTI-NFLAMMATORY DRUG 0007 Proton pump inhibitors are typically prescribed for Short-term treatment of active duodenal ulcers, gastrointes CROSS REFERENCE TO RELATED tinal ulcers, gastroesophageal reflux disease (GERD), Severe APPLICATIONS erosive esophagitis, poorly responsive Symptomatic GERD, 0001.
    [Show full text]
  • Customs Tariff - Schedule
    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2020 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, following to be employed in commercial fishing or the commercial UST, MXT, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
    [Show full text]
  • A Review on the Current Studies in Pyrazole Derivatives, Their Biological and Pharmacological Properties
    ejpmr, 2020,7(7), 867-887 SJIF Impact Factor 6.222 EUROPEAN JOURNAL OF PHARMACEUTICAL Review Article Pasha et al. European Journal of Pharmaceutical and Medical Research AND MEDICAL REEARCH ISSN 2394-3211 www.ejpmr.com EJPMR A REVIEW ON THE CURRENT STUDIES IN PYRAZOLE DERIVATIVES, THEIR BIOLOGICAL AND PHARMACOLOGICAL PROPERTIES Sadeq Hamood Saleh Azzam1 and M. A. Pasha2* 1Department of Studies in Chemistry, Janana Bharathi Campus, Bangalore University, Bangalore–560 056, India. 2Assistant Professor, Dept. of Chemistry, Sana’a University, Sana’a, Yemen. *Corresponding Author: M. A. Pasha Assistant Professor, Dept. of Chemistry, Sana’a University, Sana’a, Yemen. Article Received on 20/05/2020 Article Revised on 10/06/2020 Article Accepted on 30/06/2020 ABSTRACT The purpose of this present review is to highlight an overview of the versatile biological and pharmacological activities of pyrazole derivatives. The review deals with recent literature survey on the reported methods of synthesis and biological studies on pyrazole derivatives that are considered as most active heterocyclic compounds in nature; which possess a wide range of biological and various pharmacological activities such as: anti diabetic, hypnotic sedative, anti-inflammatory, antimicrobial, anticonvulsant, anthelmintic, antihypertensive, antiviral, anticancer, antioxidant, analgesic, antipyretic, antibacterial, anti-tuberculosis and so on. KEYWORDS: Pyrazole derivatives; biological activity; pharmacological activity; chemical synthesis. INTRODUCTION analyzed by comparing with the properties of benzene The term pyrazole was coined by Knorr in 1883. derivatives.[13] Pyrazole refers to a group of simple aromatic heterocyclic compounds which impart pharmacological Very similar to the other nitrogen containing effects on human beings. They are classified as alkaloids, heterocycles, different tautomeric structures can be although they are rare in nature.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,682,043 B2 Goldman (45) Date of Patent: Jun
    USOO9682043B2 (12) United States Patent (10) Patent No.: US 9,682,043 B2 Goldman (45) Date of Patent: Jun. 20, 2017 (54) METHOD OF PREPARATION OF MIXED FOREIGN PATENT DOCUMENTS PHASE CO-CRYSTALS WITH ACTIVE AGENTS JP 63-240936 A 10, 1988 JP 2003-522097 A 8, 1999 JP 20O2506876 A 3, 2002 (75) Inventor: David Goldman, Portland, CT (US) JP 2002356419 A 12/2002 WO WO99/47543 A2 9, 1999 (73) Assignee: MedCrystallForms, LLC, Hunt Valley, WO WO O2/O55,059 A2 T 2002 MD (US) WO WO O3/101392 A2 12/2003 WO WO 2004/043358 5, 2004 (*) Notice: Subject to any disclaimer, the term of this WO WO 2004/078161 A1 9, 2004 patent is extended or adjusted under 35 WO WO 2004/082666 9, 2004 U.S.C. 154(b) by 537 days. OTHER PUBLICATIONS (21) Appl. No.: 11/008,034 Lide CRC Handbook of Chemistry and Physics 2003 p. 3-246 and 3-480. (22) Filed: Dec. 9, 2004 Meyerson et al. “Crystals, Crystal Growth, and Nucleation' Hand book of Industrial Crystallization Ed. Meyerson. Woburn: But (65) Prior Publication Data terworth-Heinemann 2002 p. 33, and 38-39.* US 2005/0181041 A1 Aug. 18, 2005 Payne et al. International Journal of Pharmaceutics 1999 177:231 245-k Zhang et al. Journal of Pharmaceutical Sciences 2007 96(5):990 Related U.S. Application Data 995.* (60) Provisional application No. 60/528.232, filed on Dec. Reutzel-Edens et al. Solid-state pharmaceutical development: 9, 2003, provisional application No. 60/559,862, filed Ensuring stability through salt and polymorph screening.
    [Show full text]